TD Cowen Reiterates Buy Rating on Gilead Sciences (NASDAQ: GILD)

  • TD Cowen reiterated its Buy rating on Gilead Sciences.
  • Gilead expects HIV and oncology treatments to drive growth, reporting its strongest growth in over a decade in the third quarter.
  • The company is building an inflammation business and targets 10% to 11% base business growth by 2026.

TD Cowen reiterated its Buy rating on Gilead Sciences (NASDAQ: GILD), which develops HIV and oncology treatments and is building an inflammation business. Shares were trading at $168.77 when the alert was posted.

Gilead shares gained 8.8% over the past month, compared with a 4% decline in the Zacks S&P 500 composite and a 4.2% gain in the Zacks Medical - Biomedical and Genetics industry, as highlighted by Zacks Investment Research. Gilead has also been among the most searched-for stocks on Zacks.com recently.

Gilead expects HIV and oncology treatments to drive growth through the rest of the decade, as highlighted by MarketBeat. CEO Dan O’Day said the company recorded its strongest growth in more than a decade in the third quarter, citing HIV treatments, TRODELVY and LIVDELZI. He said Gilead is diversifying its HIV business before BIKTARVY’s patent expires in 2036.

Gilead is also building an inflammation business for the 2030s. O’Day said phase 2 data for an oral alpha-4-beta-7 candidate showed potential for injectable-level efficacy in a pill with favorable tolerability. The company plans to pursue the candidate alone and in combination with other treatments.

CFO Andy Dickinson said Gilead expects its base business, excluding Veklury, to grow 10% to 11% in 2026, as highlighted by MarketBeat. Gilead is targeting approximately $1 billion in 2026 Yeztugo sales, up from approximately $800 million. Dickinson expects business and earnings-per-share growth in 2028 despite an anticipated $1.5 billion Biktarvy pricing headwind.

About the Author
Alex Lavoie

Market news and analyst rating coverage

Alex Lavoie covers market-moving news and analyst activity for the FMP blog, summarizing price-target changes, upgrades and downgrades, earnings results, and company developments. The focus is on turning timely market events into concise, data-backed updates that help readers stay current on the companies they follow.

Financial data for every need

Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions — all accessible via API.

Create Free Account